egion of the lung 1 day post exposure, with subpleuralfibrosis occurring at 2 weeks post exposurethat progressed through 6 weeks of follow-up. Nofibrosis was observed in mice exposed <strong>to</strong> 1 mg/m 3 ofMWCNT or in mice exposed <strong>to</strong> 30 mg/m 3 of nanoscalecarbon black.Subchronic inhalation studies with MWCNT havealso been conducted in labora<strong>to</strong>ry studies withrats <strong>to</strong> assess the potential dose-response <strong>and</strong> timecourse for developing pulmonary effects [Arkema2008; Ma-Hock et al. 2009; Pauluhn 2010a]. Ma-Hock et al. [2009] reported on the results of a 90-day inhalation (head-nose) study with rats exposedat concentrations of 0.1, 0.5, or 2.5 mg/m 3 MWCNT(BASF Nanocyl NC 7000) for 6 hr/day, 5 days/weekfor 13 weeks with a resultant lung burden of 47–1170 µg/rat. No systemic <strong>to</strong>xicity was observed,but the exposure caused hyperplastic responsesin the nasal cavity <strong>and</strong> upper airways (larynx <strong>and</strong>trachea), <strong>and</strong> granuloma<strong>to</strong>us inflammation in thelung <strong>and</strong> in lung-associated lymph nodes at all exposureconcentrations. The incidence <strong>and</strong> severityof the effects were concentration-related. No lungfibrosis was observed but pronounced alveolar lipoproteinosisdid occur.Ellinger-Ziegelbauer <strong>and</strong> Pauluhn [2009] conducteda short-term inhalation bioassay (beforethe Pauluhn 2010a subchronic study) <strong>to</strong> investigatethe dependence of pulmonary inflammationresulting from exposure <strong>to</strong> one type of MWCNT(Bayer Baytubes®), which was highly agglomerated<strong>and</strong> contained a small amount of cobalt (residualcatalyst). Groups of rats were exposed <strong>to</strong> 11 mg/m 3MWCNT containing either 0.53% or 0.12% cobalt<strong>to</strong> assess differences in pulmonary <strong>to</strong>xicity becauseof metal contamination. Another group of rats wasexposed <strong>to</strong> 241 mg/m 3 MWCNT (0.53% cobalt)<strong>to</strong> serve the purpose of hazard identification. Allanimals were exposed <strong>to</strong> a single nose-only inhalationexposure of 6 hr followed by a post-exposureperiod of 3 months. Time course of MWCNTrelatedpulmonary <strong>to</strong>xicity was compared with ratsexposed <strong>to</strong> quartz in post-exposure weeks 1, 4, <strong>and</strong>13 <strong>to</strong> distinguish early, possibly surface area/activityrelatedeffects from retention-related poorly solubleparticle effects. Rats exposed <strong>to</strong> either quartz orMWCNT resulted in somewhat similar patternsof concentration-dependent pulmonary inflammationduring the early phase of the study. Thepulmonary inflammation induced by quartz increasedduring the 3 months post-exposure period,whereas that induced by MWCNT regressed ina concentration-dependent manner. The time courseof pulmonary inflammation associated with retainedMWCNT was independent on the concentrationof residual cobalt. Pauluhn [2010a], using the sameMWCNT (0.53% cobalt) used in the study byEllinger-Ziegelbauer <strong>and</strong> Pauluhn [2009] exposedrats (nose-only) at concentrations 0.1, 0.4, 1.5, <strong>and</strong>6 mg/m 3 for 6 hr/day, 5 days/week for 13 weeks. Theaerosolized MWCNT were described as being highlyagglomerated (mean diameter of 3 µm). Lungclearance of MWCNT at the low doses was slow,with a marked inhibition of clearance at 1.5 <strong>and</strong>6 mg/m 3 . His<strong>to</strong>pathology analysis at 6 months postexposure revealed exposure-related lesions in theupper respira<strong>to</strong>ry (e.g., goblet cell hypermetaplasia<strong>and</strong>/or metaplasia) <strong>and</strong> lower respira<strong>to</strong>ry (e.g., inflammationin the bronchiole-alveolar region) tractin animals exposed at concentrations of 0.4, 1.5, <strong>and</strong>6 mg/m 3 , as well as inflamma<strong>to</strong>ry changes in thedistal nasal cavities that were similar <strong>to</strong> those foundby Ma-Hock et al. [2009]. In rats exposed at 6 mg/m 3 , a time-dependent increase of bronchioloalveolarhyperplasia was observed, as well as changes ingranulomas <strong>and</strong> an increase in collagen depositionthat persisted through the 39-week post-exposureobservation period. No treatment-related effectswere reported for rats exposed at 0.1 mg/m 3 .In a report submitted by Arkema [2008] <strong>to</strong> EPA, ratsexposed (nose only) <strong>to</strong> agglomerates of MWCNT(Arkema) at concentrations of 0.1, 0.5, <strong>and</strong> 2.5 mg/m 3 for 6 hr/day for 5 days exhibited his<strong>to</strong>pathologicaleffects that were consistent with those reportedby Ma-Hock et al. [2009], Ellinger-Ziegelbauer <strong>and</strong>Pauluhn [2009] <strong>and</strong> Pauluhn [2010a]. An increase ofvarious cy<strong>to</strong>kines <strong>and</strong> chemokines in the lung, alongwith the development of granulomas were found inthe 0.5 <strong>and</strong> 2.5 mg/m 3 exposure groups, while notreatment-related effects were reported at 0.1 mg/m 3 .18 NIOSH CIB 65 • <strong>Carbon</strong> <strong>Nanotubes</strong> <strong>and</strong> <strong>Nanofibers</strong>
3.3 SWCNT <strong>and</strong> MWCNTIntraperi<strong>to</strong>neal StudiesIntraperi<strong>to</strong>neal injection studies in rodents havebeen frequently used as screening assays for potentialmesotheliogenic activity in humans. To date,exposures <strong>to</strong> only a few fiber types are known <strong>to</strong>produce mesotheliomas in humans; these includethe asbes<strong>to</strong>s minerals <strong>and</strong> erionite fibers. Severalanimal studies [Takagi et al. 2008; Pol<strong>and</strong> et al.2008; Muller et al. 2009; Varga <strong>and</strong> Szendi 2010;Murphy et al. 2011] have been conducted <strong>to</strong> investigatethe hazard potential of various sizes <strong>and</strong> dosesof MWCNT <strong>and</strong> SWCNT <strong>to</strong> cause a carcinogenicresponse. Takagi et al. [2008] reported on the intraperi<strong>to</strong>nealinjection of 3 mg of MWCNT in p53+/- mice (a tumor-sensitive, genetically engineeredmouse model), in which approximately 28% of thestructures were > 5 µm in length with an averagediameter of 100 nm. After 25 weeks, 88% of micetreated with MWCNT revealed moderate <strong>to</strong> severefibrotic peri<strong>to</strong>neal adhesions, fibrotic peri<strong>to</strong>nealthickening, <strong>and</strong> a high incidence of macroscopicperi<strong>to</strong>neal tumors. His<strong>to</strong>logical examination foundmesothelial lesions near fibrosis <strong>and</strong> granulomas.Similar findings were also seen in the crocidoliteasbes<strong>to</strong>s-treated positive control mice. Minimalmesothelial reactions <strong>and</strong> no mesotheliomas wereproduced by the same dose of (nonfibrous) C 60fullerene. Pol<strong>and</strong> et al. [2008] reported that theperi<strong>to</strong>neal (abdominal) injection of long MW-CNT—but not short MWCNT—induced inflammation<strong>and</strong> granuloma<strong>to</strong>us lesions on the abdominalside of the diaphragm at 1 week post-exposure.This study, in contrast <strong>to</strong> the Takagi et al. [2008]study, used wild type mice exposed <strong>to</strong> a much lowerdose (50 µg) of MWCNT. Although this studydocumented acute inflammation, it did not evaluatewhether this inflammation would persist <strong>and</strong>progress <strong>to</strong> mesothelioma. Murphy et al. [2011]found similar findings in C57BI/6 mice that were injectedwith different types of MWCNT composed ofdifferent tube dimensions <strong>and</strong> characteristics (e.g.,tangled) or injected with mixed-length amosite asbes<strong>to</strong>s.Mice were injected with a 5 µg dose directlyin<strong>to</strong> the pleural space <strong>and</strong> evaluated after 24 hours, 1,NIOSH CIB 65 • <strong>Carbon</strong> <strong>Nanotubes</strong> <strong>and</strong> <strong>Nanofibers</strong>4, 12, <strong>and</strong> 24 weeks. Mice injected with long (> 15µm) MWCNT or asbes<strong>to</strong>s showed significantlyincreased granulocytes in the pleural lavage, comparedwith the vehicle control at 24 hours post exposure.Long MWCNT caused rapid inflammation<strong>and</strong> persistent inflammation, fibrotic lesions, <strong>and</strong>mesothelial cell proliferation at the parietal pleuralsurface at 24 weeks post exposure. Short (< 4 µm)<strong>and</strong> tangled MWCNT did not cause a persistent inflamma<strong>to</strong>ryresponse <strong>and</strong> were mostly cleared fromthe intrapleural space within 24 hours.A lack of a carcinogenic response was reported byMuller et al. [2009] <strong>and</strong> Varga <strong>and</strong> Szendi [2010]in rats, <strong>and</strong> by Liang et al. [2010] in mice, followingintraperi<strong>to</strong>neal injection or implantation ofMWCNT or SWCNT. No mesotheliomas werenoted 2 years after intraperi<strong>to</strong>neal injection ofMWCNT in rats at a single dose of 2 or 20 mg[Muller et al. 2009] or MWCNT (phosphorylcholine-grafted)in mice when given daily doses ofeither 10, 50, or 250 mg/kg <strong>and</strong> evaluated at day28 [Liang et al. 2010]. However, the MWCNT samplesused in the Muller et al. [2009] <strong>and</strong> Liang etal. [2010] studies were very short (avg. < 1 µm inlength observed by Muller et al. [2009] <strong>and</strong> < 2 µmin length observed by Liang et al. [2010]), <strong>and</strong> thefindings were consistent with the low biologicalactivity observed in the Pol<strong>and</strong> et al. [2008] studywhen mice were exposed <strong>to</strong> short MWCNT. Varga<strong>and</strong> Szendi [2010] reported on the implantation ofeither MWCNT or SWCNT in F-344 rats (six pergroup) at a dose of 10 mg (25 mg/kg bw). Gelatincapsules containing either SWCNT (< 2 nm diameters× 4–15 µm lengths), MWCNT (10–30 nm diameters× 1–2 µm lengths), or crystalline zinc oxide(negative control) were implanted in<strong>to</strong> the peri<strong>to</strong>nealcavity. His<strong>to</strong>logical examination at 12 monthsrevealed only a granuloma<strong>to</strong>us reaction of foreignbody type with epithelioid <strong>and</strong> multinucleated giantcells in CNT-exposed animals. No information wasreported on what effect the delivery of SWCNT <strong>and</strong>MWCNT in gelatin capsules had on their dispersionin the peri<strong>to</strong>neal given the tendency of CNT <strong>to</strong>agglomerate. If SWCNT <strong>and</strong> MWCNT remainedagglomerated following delivery, this may have19
- Page 1 and 2: CURRENT INTELLIGENCE BULLETIN 65Occ
- Page 3 and 4: Current Intelligence Bulletin 65Occ
- Page 5 and 6: ForewordThe Occupational Safety and
- Page 7 and 8: Executive SummaryOverviewCarbon nan
- Page 9 and 10: 2009; Pauluhn 2010a; Porter et al.
- Page 11 and 12: neurogenic sig nals from sensory ir
- Page 13 and 14: possible. Until the results from an
- Page 15 and 16: ••Follow exposure and hazard as
- Page 17 and 18: Periodic Evaluations••Evaluatio
- Page 19 and 20: ContentsForeword ..................
- Page 21 and 22: A.3.2 Comparison of Short-term and
- Page 23 and 24: ESPFeFMPSFPSSgGMGSDHCLHECHEPAhrISOI
- Page 25 and 26: AcknowledgementsThis Current Intell
- Page 27 and 28: 1 IntroductionMany nanomaterial-bas
- Page 29: 2 Potential for ExposureThe novel a
- Page 32 and 33: CNMs, with MWCNT agglomerates obser
- Page 34 and 35: composite materials with local exha
- Page 36 and 37: information on air contaminants. Sa
- Page 39 and 40: 3 Evidence for Potential Adverse He
- Page 41 and 42: decreasing agglomerate size increas
- Page 43: examined up to 60 days post-exposur
- Page 47 and 48: The same potency sequence was obser
- Page 49 and 50: Table 3-3. Findings from published
- Page 51 and 52: Table 3-5. Findings from published
- Page 53 and 54: Table 3-6. Findings from published
- Page 55 and 56: Table 3-7 (Continued). Findings fro
- Page 57: Table 3-8. Findings from published
- Page 60 and 61: length, respectively) [Muller et al
- Page 63 and 64: 5 CNT Risk Assessment and Recommend
- Page 65 and 66: A-6). Risk estimates derived from o
- Page 67 and 68: Table 5-4. Factors, assumptions, an
- Page 69 and 70: and analytical methods. NIOSH is re
- Page 71 and 72: Table 5-5. Recommended occupational
- Page 73 and 74: deficits in animals or clinically s
- Page 75: (3) Rat lung dose estimationIn the
- Page 78 and 79: tasks where worker exposures exceed
- Page 80 and 81: As part of the evaluation of worker
- Page 82 and 83: Table 6-1. EC LODs and LOQs for 25-
- Page 84 and 85: 6.2 Engineering ControlsOne of the
- Page 86 and 87: Table 6-6 (Continued). Examples of
- Page 88 and 89: Table 6-7 (Continued). Engineering
- Page 90 and 91: exposure estimates for SWCNT on ind
- Page 92 and 93: Table 6-8. Respiratory protection f
- Page 94 and 95:
••Workers in areas or in jobs w
- Page 97 and 98:
7 Research NeedsAdditional data and
- Page 99 and 100:
ReferencesACGIH [1984]. Particle si
- Page 101 and 102:
Bolton RE, Vincent HJ, Jones AD, Ad
- Page 103 and 104:
eport issued on July 22, 2011. NEDO
- Page 105 and 106:
Kobayashi N, Naya M, Mizuno K, Yama
- Page 107 and 108:
Methner M, Hodson L, Geraci C [2010
- Page 109 and 110:
Human Services, Centers for Disease
- Page 111 and 112:
Piegorsch WW, Bailer AF [2005]. Qua
- Page 113 and 114:
AD, Baron PA [2003]. Exposure to ca
- Page 115:
Varga C, Szendi K [2010]. Carbon na
- Page 119 and 120:
ContentsA.1 Introduction ..........
- Page 121 and 122:
A.1 IntroductionThe increasing prod
- Page 123 and 124:
provide an informal check on the es
- Page 125 and 126:
these same dose groups; this effect
- Page 127 and 128:
Table A-1. Rodent study information
- Page 129 and 130:
the deposited (no clearance) and th
- Page 131 and 132:
The other BMDS models failed to con
- Page 133 and 134:
Figure A-2. Benchmark dose model (m
- Page 135 and 136:
Figure A-3 (continued). Benchmark d
- Page 137 and 138:
Table A-3. Benchmark dose estimates
- Page 139 and 140:
Table A-5. Benchmark dose estimates
- Page 141 and 142:
histopathology grade 2 or higher lu
- Page 143 and 144:
Table A-8. Working lifetime percent
- Page 145 and 146:
developing early-stage adverse lung
- Page 147 and 148:
Figure A-4. Dose-response relations
- Page 149 and 150:
cell surface area). However, the wo
- Page 151 and 152:
purified or unpurified (with differ
- Page 153 and 154:
Table A-9. Comparison of rat or hum
- Page 155 and 156:
A.6.1.3 Pulmonary Ventilation RateT
- Page 157 and 158:
used as the effect levels in evalua
- Page 159 and 160:
the DF estimate, although a larger
- Page 161 and 162:
or overloading, of particle clearan
- Page 163 and 164:
Table A-13. Human-equivalent retain
- Page 165 and 166:
A.7.1 Particle CharacteristicsBoth
- Page 167 and 168:
and density. The following MMAD and
- Page 169:
Table A-15. CNT lung dose normalize
- Page 172 and 173:
B.1 Key Terms Related toMedical Sur
- Page 175 and 176:
APPENDIX CNIOSH Method 5040
- Page 177 and 178:
filter. In the method evaluation, d
- Page 179 and 180:
Most of the studies on sampling art
- Page 181 and 182:
e analyzed to determine the onset o
- Page 184:
Delivering on the Nation’s promis